联合用药治疗女性精神分裂症对照研究

A Control Study of Combined Medication in Treatment of Female Schizophrenia

目的探讨阿立哌唑治疗女性精神分裂症的临床疗效及安全性。方法将68例女性精神分裂症患者随机分为2组,每组34例,研究组口服阿立哌唑,对照组口服利培酮治疗,观察8周,于治疗前及治疗2周、4周、及8周末采用阳性与阴性症状量表评定临床疗效,副反应量表评定不良反应。结果治疗8周2组PANSS评分较治疗前均显著降低(P<0.05or0.01),同期2组间评分均无显著差异(P>0.05);治疗8周末,研究组显效率58.8%有效率79.4%,对照组分别为70.6%和88.2%,2组比较无显著性差异(P>0.05);2组不良反应均轻微,研究组主要表现为兴奋激越和恶心呕吐,对照组主要表现为锥外反应、体重增加、月经紊乱和泌乳。结论阿立呱唑治疗精神分裂症的疗效与利培酮相当,对催乳素无影响,是一种安全有效的抗精神病药物,更适合女性精神病患者,值得在临床推广。

Objective To explore the clinical efficacy and safety of aripiprazole in the treatment of female schizophrenia. Methods Sixty-eight female schizophrenics were randomly assigned to two group of 34 patients each, research group took orally aripiprazole and control group did risperidone for 8 weeks. Clinical efficacies were assessed with the Positive and Negative Syndrome Scale （PANSS） and adverse reactions with the Treatment Emergent Symptom Scale （TESS） before treatment and at the end of the 2d, 4t＂, and 8t＂ week. Results By the end of the 8 week treatment, in both groups, the scores of PANSS decreased significantly comparing to the baseline （P 〈 0.05 or 0.01）, there were no significant differences in group comparisons （all P 〉 0.05）; at the end of the 8t＂ week, the obvious effective and effective rates were 58.8% and 79.4%, in the research and 70.6% and 88.2% in the control group, which showed no significant differences （P〉 0.05）. In the aspect of adverse reactions, aripiprazole group was associated with more erethism, nausea and vomit, while risperidone group was associated with more weight gain, endocrinopathy and extrapyramidal syndrome （P 〈 0.05）. Conclusion Aripiprazole has similar efficacy to risepridone in the antipsychotic treatment with mild impact on prolactin level. So aripiprazole is a safe and effective antipsychotics. Aripiprazole is more suitable for female mental patients and deserves clinical generalization.